

Supplemental materials and figures

1
2
3
4
5
6
7

Sulforaphane decreases serum selenoprotein P levels through the enhancement of lysosomal degradation independent of Nrf2

8 **1. Supplemental Materials and Methods**

9

10 **1.1. Transfection of siRNAs**

11 A transfection complex (Opti-MEM 500 μ L, 10 μ M siRNA 3 μ L, Lipofectamine[®] RNAiMAX
12 reagent 3 μ L) was prepared and added to the culture medium. Then the cells were further cultured at
13 37 °C., 5% CO₂, and 95% ambient air for 24 hours. The sequence of siRNA used is as follows
14 (synthesized by Sigma).

15 si Nrf2 # 1 F: CAAACAGAAUGGUCCUAAA

16 R: UUUAGGACCAUUCUGUUUG

17 # 2 F: CUCACAAGAGAUGAACUUA

18 R: UAAGUUCAUCUCUUGUGAG

19 # 3 F: GCUCAUACUUUAUAAGUAA

20 R: UUACUUAUAAAGUAUGAGC

21 # 4 F: CUGUUGAUUUAGACGGUAU

22 R: AUACCGUCUAAAUCAACAG

23 The control siRNA used was SIC-001, Universal Negative siRNA manufactured by Sigma.

24

25 **1.2 .Deglycosylation assay**

26 Plasma of C57BL6/J, ICR and KKAY mice was treated with deglycosylation according to the
27 protocol of Protein Deglycosylation Mix II (Biolabs, P6044S) and Western blotting was performed.

28

29 **1.3. Glucose tolerance test**

30 After treatment with SFN for 1 month, KKAY mice were fasted for 14 h, and 0.3 g/kg glucose
31 was intraperitoneally administered. Blood was collected from the tail and glucose levels were
32 measured 0-120 min after glucose treatment using Lab Gluco (RIJ, Japan, Tokyo).

33

34 **Supplemental Table 1 Antibodies used for Western blotting**

Primary antibody

anti- β -actin	A5441, clone AC-15	Sigma-Aldrich MO
anti-GPx1	ab108427	abcam
anti-GPx4	ab125066	abcam
anti-HO-1	sc-390991	Santa Cruz Biotechnology
anti-LAMP2	sc-18822	Santa Cruz Biotechnology
anti-LC-3A/B	12741S	Cell Signaling Technology
anti-Nrf2	sc-365949	Santa Cruz Biotechnology
anti-p62	511S	Cell Signaling Technology
anti-hSeP		Mita et al., 2017
anti-mSeP		Mita et al., 2017

Second antibody

anti-mouse	20051789	Dako-Agilent
anti-rabbit	20073563	Dako-Agilent
anti-rat	00063346	Dako-Agilent

35 All primary antibody were used 1/1000 dilution, and 2nd antibody were used 1/10000 dilution.

36

38 **Supplemental Table 2 Primers for RT-qPCR**

Human


<i>ATP6V1A</i>	F	AGGCTGAAATCGAGAACCCC
	R	GCTCGGAACCCTTCACAGAT
<i>GAPDH</i>	F	GCACCGTCAGGCTGAGAAC
	R	TGGTGAAGACGCCAGTGGA
<i>HO-1</i>	F	CCAGCAACAAAGTGCAAGATTC
	R	TCACATGGCATAAAGCCCTACAG
<i>Nrf2</i>	F	TCCAGTCAGAAACCAGTGGAT
	R	GAATGTCTGCGCCAAAAGCTG
<i>SELENOP</i>	F	CCCCCAGCCTGGAGCATAAG
	R	TGCACAGGTATCAGCTGGCTT

Mouse

<i>Selenop</i>	F	AGCTCTGCTTGTTACAAAGCC
	R	CAGGTCTTCCAATCTGGATGC

40 Supplementary Figure 1

41



42

43

44

45


46 **Supplemental Figure 1. Effect of SNF on intracellular SeP at the protein level in a dose-**
47 **dependent manner.**

48 HepG2 cells cultured with selenite (100 nM) were treated with the indicated concentration of SFN
49 for 24 hr. The cell lysate was then subjected to Western blotting. All blots were performed on
50 independent membranes and were done with the same sample volume apply.

51

52 Supplementary Figure 2

53



54

55

56 **Supplemental Figure 2. Molecular size shift of SeP by glycosylation in different strains of mice.**

57 Serum of C57BL6/J, ICR and KKAy mice were treated with deglycosylation according to the Protein


58 Deglycosylation Mix II (Biolabs, P6044S) protocol and WB of SeP was performed.

59

60

61 Supplementary Figure 3

62



63

64

65 **Supplemental Figure 3. Detailed image of Figure 2a.**


66 Magnified images of Figure 2a are shown. The scale bar indicates 20 μm.

67

68

69

70




75 **Supplemental Figure 4. Effect of Nrf2 knockdown on SeP mRNA.**

76 Control and Nrf2 siRNA #1 were introduced into HepG2 cells, cultured for 24 hr and treated with

77 SFN at the indicated concentrations for 24 hr. Total RNA was collected and SeP mRNA was measured

78 using RT-qPCR. Data indicates mean \pm S.D



83

84

85 **Supplemental Figure 5. Effect of Nrf2 knockdown on SeP protein expression in HepG2 cells.**

86 Control and four types of Nrf2 siRNA were transfected into HepG2 cells and cultured for 24 hr. Cell


87 lysates were collected, and WB was performed (upper panel). Knockdown efficiency was examined

88 using RT-qPCR (lower panel). Data indicates mean \pm S.D. All blots were performed on independent


89 membranes and were done with the same sample volume apply.

90

91


96 **Supplemental Figure 6. Effect of SFN on the mRNA of ATP6V1A in mice liver.**

97 C57BL6/J male mice (n=5) were treated with SFN (10mg/kg) by i.p., every 12 hr for 48 hr. mRNA
98 levels of Atp6v1a in the liver were measured by RT-qPCR (left panel). KKAY mice (n=4) were
99 administered 10 mg/kg SFN every day for 1 month. Hepatic Atp6v1a mRNA levels were measured
100 by RT-qPCR. The data is expressed as Mean \pm S.D.



108 **Supplemental Figure 7. Effect of SFN on GPx1 protein and mRNA levels in vivo.**

109 Livers were taken from WT or KKAY mice treated with Vehicle and SFN, and the expression level of
 110 GPx1 was measured by WB. The GPx1 band was corrected and quantified with β -actin, expressed as
 111 $N = 5$ or 4 , Mean \pm S.D., and shown as a relative value with the control as 1. * $P < 0.05$ vs control.
 112 All blots were performed on independent membranes and were done with the same sample volume
 113 apply.



116


117 **Supplemental Figure 8. Blood glucose levels and glucose sensitivity of diabetic-mice treated with**
 118 **SFN.**

119 The change in blood glucose levels in KKAY mice treated with Vehicle and SFN was measured. A
 120 glucose tolerance test was conducted after treatment with SFN.

121 Supplemental Figure 6. Elevated GSH levels attenuate the effects of SFN

122 (A) Liver GSH values of normal C57BL6/J mice and diabetic KKAY mice. The quantified data is
 123 expressed as N=4, Mean ± S.D., and shown as a relative value with the control as 1. * P < 0.05 vs
 124 control. (B) Intracellular and extracellular SeP expression of HepG2 cells treated with NAC and SFN
 125 for 24hr.

126



129

130 **Supplemental Figure 9. Glutathione content in the liver of KKAY mice and the effect of NAC**
 131 **on SeP reduction by SFN in HepG2 cells.**

132 (a) Liver GSH values of normal C57BL6/J mice and diabetic KKAY mice. The quantified data is
 133 expressed as N=4, Mean ± S.D., and shown as a relative value with the control as 1. * P < 0.05 vs
 134 control. (b) Intracellular SeP expression of HepG2 treated with NAC (3 mM) and SFN (6 μM) for
 135 24hr. All blots were performed on independent membranes and were done with the same sample
 136 volume apply.

137

Fig1.b




Fig1.d






Fig2.d



146

Fig2.e




147

148 **Supplemental Figure 11. Uncropped data of WB figure 2.**

149

150 **Supplementary Figure 12**



151

152

153 **Supplemental Figure 12. Uncropped data of WB figure 3.**

154

Fig4.a




Fig4.c




Fig4.d




Fig4.f






Fig4.g



160
161
162
163


Supplemental Figure 1



164
165
166
167





Supplemental Figure 14. Uncropped data of WB S1.

Supplemental Figure 2




168
169
170
171

Supplemental Figure 15. Uncropped data of WB S2.



175 **Supplemental Figure 16. Uncropped data of WB S5.**



186

187

188 **Supplemental Figure 17. Uncropped data of WB S7**

189

190

191

192

193

194

195


196

197

198

199

b)



200

201

202

203

204 **Supplemental Figure 18. Uncropped data of WB S9**

205